NCI-2022-09254

A Randomized Phase II Study of Capmatinib Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

This Phase II research study is investigating whether adding Ramucirumab to the combination of Capmatinib and Osimertinib improves outcomes for patients with advanced or recurrent non-small cell lung cancer that has both an EGFR mutation and MET amplification. EGFR-Mutant means the cancer has a mutation in the Epidermal Growth Factor Receptor (EGFR) gene. These mutations are common in some types of lung cancer and can be targeted by specific drugs. MET-Amplified means the cancer cells have an increased number of copies of the MET gene, leading to overexpression of the MET protein. This amplification can contribute to cancer growth and resistance to other treatments. Capmatinib is MET inhibitor, targeting the MET protein which can be involved in cancer growth and spread. Osimertinib is an EGFR inhibitor, targeting the EGFR protein, another driver of cancer growth in some lung cancers. The study is comparing the combination of all three drugs to the combination of Capmatinib and Osimertinib alone.

Phase 2: An advanced point of testing, where they're trying to confirm if a treatment works well.

non-small cell lung cancer (NSCLC): A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05642572

Clinical Trial Site: Einstein

To see all available clinical trials click here.